Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
Yang JCH, Brose MS, Castro G, Kim ES, Lassen UN, Leyvraz S, Pappo A, López-Ríos F, Reeves JA, Fellous M, Penault-Llorca F, Rudzinski ER, Tabatabai G, Vassal G, Drilon A, Trent J.
Yang JCH, et al. Among authors: reeves ja.
BMC Cancer. 2022 Jun 7;22(1):625. doi: 10.1186/s12885-022-09687-x.
BMC Cancer. 2022.
PMID: 35672677
Free PMC article.